» Articles » PMID: 35922609

Bariatric Surgery in Migraine Patients: CGRP Level and Weight Loss

Overview
Journal Obes Surg
Date 2022 Aug 3
PMID 35922609
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Obesity makes migraine more prevalent and severe. Serum level of calcitonin gene-related peptide (CGRP) is associated with the severity of migraine attacks. Although the effect of weight and bariatric surgery has been studied on migraine, the role of CGRP in migraine remission after weight loss surgery needs more investigation.

Methods: Patients with severe obesity who were bariatric surgery candidates and had been diagnosed with chronic migraine were included in this study. Weight, BMI, number of days with headache in the past 3 months, and severity of headaches in 10-point Likert VAS, Migraine Disability Assessment Scale (MIDAS) and Migraine Specific Quality of life (MSQ) questionnaire scores, and serum CGRP levels were evaluated before and within 6-10 months after surgery.

Result: Sixty patients with chronic migraine with severe obesity were included. Ninety-five percent of patients reported a significantly lower number of attacks (21 to 8, p < 0.001) and severity of headaches within 90-day (7.7 to 4.8, p < 0.001); MIDAS (64.4 to 25.5, p < 0.001) and MSQ scores (44.6 to 26.8, p < 0.001) and CGRP level (252.7 to 130.1, p < 0.001) were significantly reduced after surgery with a mean follow-up of 7.5 months. Changes in MIDAS, MSQ, and CGRP were significantly associated with weight-related variables.

Conclusion: Bariatric surgery decreases the frequency of migraine attacks, lessens the severity of headaches, and improves the quality of life and disability as well as CGRP plasma levels, suggesting CGRP as a possible etiology in the migraine-obesity link.

Citing Articles

Untangling the mess of CGRP levels as a migraine biomarker: an in-depth literature review and analysis of our experimental experience.

Garate G, Pascual J, Pascual-Mato M, Madera J, Munoz-San Martin M, Gonzalez-Quintanilla V J Headache Pain. 2024; 25(1):69.

PMID: 38684990 PMC: 11057141. DOI: 10.1186/s10194-024-01769-4.


Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study.

Guerzoni S, Lo Castro F, Brovia D, Baraldi C, Pani L Neurol Sci. 2023; 45(4):1661-1668.

PMID: 37926748 DOI: 10.1007/s10072-023-07167-z.

References
1.
Di Vincenzo A, Beghetto M, Vettor R, Tana C, Rossato M, Bond D . Effects of Surgical and Non-surgical Weight Loss on Migraine Headache: a Systematic Review and Meta-Analysis. Obes Surg. 2020; 30(6):2173-2185. DOI: 10.1007/s11695-020-04429-z. View

2.
Kilinc E, Dagistan Y, Kukner A, Yilmaz B, Agus S, Soyler G . Salmon calcitonin ameliorates migraine pain through modulation of CGRP release and dural mast cell degranulation in rats. Clin Exp Pharmacol Physiol. 2018; 45(6):536-546. DOI: 10.1111/1440-1681.12915. View

3.
Henson B, Hollingsworth H, Nevois E, Herndon C . Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines. J Pain Palliat Care Pharmacother. 2019; 34(1):22-31. DOI: 10.1080/15360288.2019.1690616. View

4.
Bond D, Vithiananthan S, Nash J, Thomas J, Wing R . Improvement of migraine headaches in severely obese patients after bariatric surgery. Neurology. 2011; 76(13):1135-8. PMC: 3068014. DOI: 10.1212/WNL.0b013e318212ab1e. View

5.
Nicholson R, Bigal M . Screening and behavioral management: obesity and weight management. Headache. 2008; 48(1):51-7. PMC: 2408879. DOI: 10.1111/j.1526-4610.2007.00975.x. View